trending Market Intelligence /marketintelligence/en/news-insights/trending/Q0aN9VW4jBAo6BM3IT6XTw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Eleven Biotherapeutics CFO resigns; interim replacement named

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Eleven Biotherapeutics CFO resigns; interim replacement named

John McCabe resigned as CFO of Eleven Biotherapeutics Inc., effective Oct. 20.

McCabe did not resign due to any disagreements relating to the company's operations, policies or practices or any other company officer or director.

Eleven Biotherapeutics appointed Richard Fitzgerald as interim CFO, effective Oct. 13.

Fitzgerald most recently served as a consultant to private life science based companies from July through October. Previously, Fitzgerald served as CFO of medical device maker PAVmed Inc. from October 2015 through March 2017.